Expression/NN
of/IN
c-fos/NN
correlates/VBZ
with/IN
IFN-alpha/NN
responsiveness/NN
in/IN
Philadelphia/NN
chromosome/NN
positive/JJ
chronic/JJ
myelogenous/JJ
leukemia/NN
./.

This/DT
study/NN
evaluates/VBZ
(/(
i/LS
)/)
constitutive/JJ
levels/NNS
of/IN
oncogene/NN
and/CC
p53/NN
transcripts/NNS
in/IN
chronic/JJ
phase/NN
CML/NN
patients/NNS
and/CC
(/(
ii/LS
)/)
their/PRP$
modulations/NNS
subsequent/JJ
to/TO
in/FW
vivo/FW
therapy/NN
with/IN
rIFN-alpha/NN
2c/NN
./.
=====
Peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
pbmc/NN
)/)
and/CC
bone/NN
marrow/NN
cells/NNS
of/IN
26/CD
patients/NNS
were/VBD
examined/VBN
for/IN
c-fos/NN
,/,
c-myc/NN
,/,
p53/NN
and/CC
the/DT
hybrid/NN
bcr/abl/NN
mRNA/NN
levels/NNS
./.
=====
Results/NNS
indicated/VBD
that/IN
(/(
i/LS
)/)
constitutive/JJ
c-fos/NN
transcript/NN
levels/NNS
are/VBP
significantly/RB
higher/JJR
in/IN
patients/NNS
subsequently/RB
responding/VBG
to/TO
IFN-alpha/NN
therapy/NN
(/(
p/NN
</JJR
0.01/CD
)/)
and/CC
positively/RB
correlated/VBN
with/IN
the/DT
proportion/NN
of/IN
lymphocytes/NNS
(/(
r/NN
=/JJ
0.6895/CD
,/,
p/NN
</JJR
0.01/CD
)/)
and/CC
negatively/RB
with/IN
the/DT
proportion/NN
of/IN
immature/JJ
cells/NNS
(/(
r/NN
=/JJ
-0.568/CD
,/,
p/NN
</JJR
0.01/CD
)/)
contained/VBN
in/IN
the/DT
pbmc/NN
preparations/NNS
tested/VBN
,/,
(/(
ii/LS
)/)
constitutive/JJ
mRNA/NN
levels/NNS
of/IN
the/DT
hybrid/NN
bcr/abl/NN
,/,
c-myc/NN
and/CC
p53/NN
are/VBP
positively/RB
correlated/VBN
with/IN
each/DT
other/JJ
,/,
but/CC
failed/VBD
to/TO
relate/VB
to/TO
disease/NN
parameters/NNS
,/,
and/CC
(/(
iii/LS
)/)
acute/JJ
and/CC
chronic/JJ
in/FW
vivo/FW
exposure/NN
to/TO
IFN-alpha/NN
is/VBZ
accompanied/VBN
by/IN
upregulation/NN
of/IN
c-fos/NN
and/CC
downregulation/NN
of/IN
c-myc/NN
mRNA/NN
levels/NNS
in/IN
responder/NN
patients/NNS
./.